Cargando…

The potency of luliconazole against clinical and environmental Aspergillus nigri complex

BACKGROUND AND OBJECTIVES: Black Aspergillus strains including, Aspergillus niger and A. tubingensis, are the most cause of otomycosis with worldwide distribution. Although, amphotericin B was a Gold standard for the treatment of invasive fungal infection for several decades, it gradually replaced b...

Descripción completa

Detalles Bibliográficos
Autores principales: Hivary, Sahar, Fatahinia, Mahnaz, Halvaeezadeh, Marzieh, Mahmoudabadi, Ali Zarei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tehran University of Medical Sciences 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048962/
https://www.ncbi.nlm.nih.gov/pubmed/32148683
_version_ 1783502373594857472
author Hivary, Sahar
Fatahinia, Mahnaz
Halvaeezadeh, Marzieh
Mahmoudabadi, Ali Zarei
author_facet Hivary, Sahar
Fatahinia, Mahnaz
Halvaeezadeh, Marzieh
Mahmoudabadi, Ali Zarei
author_sort Hivary, Sahar
collection PubMed
description BACKGROUND AND OBJECTIVES: Black Aspergillus strains including, Aspergillus niger and A. tubingensis, are the most cause of otomycosis with worldwide distribution. Although, amphotericin B was a Gold standard for the treatment of invasive fungal infection for several decades, it gradually replaced by fluconazole and /or voriconazole. Moreover, luliconazole, appears to offer the best potential for in vitro activity against black Aspergillus strains. The aim of the present study was to compare the in vitro activity luliconazole, with commonly used antifungals against clinical and environmental strains of black Aspergillus. MATERIALS AND METHODS: Sixty seven (37 clinical and 30 environmental) strains of black Aspergillus were identified using morphological and molecular technique (β-Tubulin gene). In addition, antifungal susceptibility test was applied according to CLSI M38 A2. The results were reported as minimum inhibitory concentration (MIC) or minimum effective concentration (MEC) range, MIC(50) or MEC(50), MIC(90) or MEC(90) and MIC geometric (GM) or MECGM. RESULTS: Aspergillus niger was the common isolate followed by, A. tubingensis in both clinical and environmental strains. The lowest MIC range, MIC(50), MIC(90), and MICGM was attributed to luliconazole in clinical strains. The highest resistant rate was found in amphotericin B for both clinical (86.5%) and environmental (96.7%) strains whereas 54.1% of clinical and 30% of environmental isolates were resistant to caspofungin. Clinical strains of Aspergillus were more sensitive to voriconazole (86.7%) than environmental strains (70.3%). On the other hand, 83.8% of clinical and 70% of environmental isolates were resistant to posaconazole. CONCLUSION: Luliconazole versus amphotericin B, voriconazole, posaconazole and caspofungin is a potent antifungal for Aspergillus Nigri complex. The in vitro extremely antifungal efficacy against black Aspergillus strains of luliconazole, is different from those of other used antifungals.
format Online
Article
Text
id pubmed-7048962
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Tehran University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-70489622020-03-06 The potency of luliconazole against clinical and environmental Aspergillus nigri complex Hivary, Sahar Fatahinia, Mahnaz Halvaeezadeh, Marzieh Mahmoudabadi, Ali Zarei Iran J Microbiol Original Article BACKGROUND AND OBJECTIVES: Black Aspergillus strains including, Aspergillus niger and A. tubingensis, are the most cause of otomycosis with worldwide distribution. Although, amphotericin B was a Gold standard for the treatment of invasive fungal infection for several decades, it gradually replaced by fluconazole and /or voriconazole. Moreover, luliconazole, appears to offer the best potential for in vitro activity against black Aspergillus strains. The aim of the present study was to compare the in vitro activity luliconazole, with commonly used antifungals against clinical and environmental strains of black Aspergillus. MATERIALS AND METHODS: Sixty seven (37 clinical and 30 environmental) strains of black Aspergillus were identified using morphological and molecular technique (β-Tubulin gene). In addition, antifungal susceptibility test was applied according to CLSI M38 A2. The results were reported as minimum inhibitory concentration (MIC) or minimum effective concentration (MEC) range, MIC(50) or MEC(50), MIC(90) or MEC(90) and MIC geometric (GM) or MECGM. RESULTS: Aspergillus niger was the common isolate followed by, A. tubingensis in both clinical and environmental strains. The lowest MIC range, MIC(50), MIC(90), and MICGM was attributed to luliconazole in clinical strains. The highest resistant rate was found in amphotericin B for both clinical (86.5%) and environmental (96.7%) strains whereas 54.1% of clinical and 30% of environmental isolates were resistant to caspofungin. Clinical strains of Aspergillus were more sensitive to voriconazole (86.7%) than environmental strains (70.3%). On the other hand, 83.8% of clinical and 70% of environmental isolates were resistant to posaconazole. CONCLUSION: Luliconazole versus amphotericin B, voriconazole, posaconazole and caspofungin is a potent antifungal for Aspergillus Nigri complex. The in vitro extremely antifungal efficacy against black Aspergillus strains of luliconazole, is different from those of other used antifungals. Tehran University of Medical Sciences 2019-12 /pmc/articles/PMC7048962/ /pubmed/32148683 Text en Copyright© 2019 Iranian Neuroscience Society http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Hivary, Sahar
Fatahinia, Mahnaz
Halvaeezadeh, Marzieh
Mahmoudabadi, Ali Zarei
The potency of luliconazole against clinical and environmental Aspergillus nigri complex
title The potency of luliconazole against clinical and environmental Aspergillus nigri complex
title_full The potency of luliconazole against clinical and environmental Aspergillus nigri complex
title_fullStr The potency of luliconazole against clinical and environmental Aspergillus nigri complex
title_full_unstemmed The potency of luliconazole against clinical and environmental Aspergillus nigri complex
title_short The potency of luliconazole against clinical and environmental Aspergillus nigri complex
title_sort potency of luliconazole against clinical and environmental aspergillus nigri complex
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048962/
https://www.ncbi.nlm.nih.gov/pubmed/32148683
work_keys_str_mv AT hivarysahar thepotencyofluliconazoleagainstclinicalandenvironmentalaspergillusnigricomplex
AT fatahiniamahnaz thepotencyofluliconazoleagainstclinicalandenvironmentalaspergillusnigricomplex
AT halvaeezadehmarzieh thepotencyofluliconazoleagainstclinicalandenvironmentalaspergillusnigricomplex
AT mahmoudabadializarei thepotencyofluliconazoleagainstclinicalandenvironmentalaspergillusnigricomplex
AT hivarysahar potencyofluliconazoleagainstclinicalandenvironmentalaspergillusnigricomplex
AT fatahiniamahnaz potencyofluliconazoleagainstclinicalandenvironmentalaspergillusnigricomplex
AT halvaeezadehmarzieh potencyofluliconazoleagainstclinicalandenvironmentalaspergillusnigricomplex
AT mahmoudabadializarei potencyofluliconazoleagainstclinicalandenvironmentalaspergillusnigricomplex